ReviewMedComm2025
Protein Kinase C Family: Structures, Biological Functions, Diseases, and Pharmaceutical Interventions.
Review in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Fyn kinase: a key mechanistic regulator and therapeutic target in tauopathy and neurodegenerative diseases.Translational neurodegeneration · 2026Review
- Silymarin and Zinc Oxide Nanoparticles Attenuate Experimental Colon Cancer in Rats Through Crosstalk of miR-192 and β-Catenin Pathways.Biomolecules · 2026Article
- Protein Kinase C-delta (PKCδ) in Neurodegeneration and Cerebral Ischemia: Molecular Mechanisms and Therapeutic Implications.Cell biochemistry and biophysics · 2026Review
- A new paradigm in Parkinson's disease: kidney-origin α-synuclein pathology driven by PKC signaling and aurothioglucose.Inflammopharmacology · 2026Review
- Suvorexant protects from ocular complications of diabetes in db/db mice.BMJ open diabetes research & care · 2026Article
- Marine medaka PKCα promotes red-spotted grouper nervous necrosis virus entry by orchestrating MYL3-mediated macropinocytosis and cofilin-dependent actin remodeling.Journal of virology · 2026Article
- Pathophysiological significance of the TRPM2 ion channel as a potential target in cancer, neurological disorders, and ischemia/reperfusion injury.Pharmacological research · 2026Review
- 'Molecular and Cellular Neuroscience': Impacts of Eight Highly Cited Articles Published in This Section ofBrain sciences · 2026Article
- Review
- PRKCB Mediates Ferroptosis-Immune Crosstalk in Acute Lung Injury: Insights from Integrated Single-Cell Transcriptomics.Journal of inflammation research · 2026Article
- Cardioprotective Signaling: Outline and Future Directions.Biomedicines · 2025Review
- Protein Kinase C Family: Structures, Biological Functions, Diseases, and Pharmaceutical Interventions.MedComm · 2025Review
- A miR-124-3p/PKC-δ Regulatory Axis Restrains Bladder Cancer Growth and Malignant Progression.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The protein kinase C (PKC) family represents pivotal regulators in cellular signaling, whose dysregulation has been implicated in diverse human diseases, including cancer, neurodegenerative disorders, and metabolic syndromes. PKCs transduce extracellular signals through lipid-mediated activation and controlled subcellular translocation. Their activity is orchestrated by a multistep life cycle, encompassing constitutive phosphorylation during maturation, second messenger-dependent activation, and agonist-driven termination. Despite extensive investigation, critical gaps remain in the isoform-specific signaling networks and the structural determinants that underlie PKC functional diversity, thereby limiting the development of targeted therapies. In this review, we provide a comprehensive analysis of the PKC family, covering isoform diversity, structural and functional attributes, physiological roles, involvement in disease pathogenesis, therapeutic targeting strategies, as well as current controversies and research challenges. PKCs precisely regulate cell fate through subtype-specific signaling networks, and their structural plasticity presents unique opportunities for therapeutic intervention. By integrating recent advances from structural biology, disease models, and clinical trials, this review proposes a unified framework of PKC regulation that bridges fundamental biology with translational innovation. Ultimately, it serves as a valuable resource for elucidating the multifaceted roles of PKCs in health and disease, while providing a conceptual basis for the rational design of next-generation therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.